Science and Education Studies

In preclinical studies of antiherpetic drug activity, it was proved that Proteflazid has polypharmacological effects. It blocks DNA polymerase and thymidine kinase in the herpes-infected cells, induces the synthesis of endogenous αand γ-interferons, has an antioxidant activity and provides an apoptosismodulating effect. In clinical practice, the etiopathogenetic drug efficacy of Proteflazid (drops for oral and topical application) is confirmed in the treatment of genital herpes infections, including the mixed infection. This systematic review, conducted on the basis of 37 clinical trials between 2000 and 2015, involving more than 1,900 patients, proves the safety and therapeutic efficacy of the Proteflazid for the treatment of herpes virus diseases in urogenital tract of both men and women.